Institut Mutualiste Montsouris
Institut Mutualiste Montsouris
Paris, France29 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Enlighten Study: The EV-ICD Post Approval Registry | Arrhythmias, Cardiac, Cardiac Conduction System Disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tachycardia, cardiovascular disorder, heart disorder | Active, not recruiting | Not stated | 2026-10-08 | NCT06048731 | |
| REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men | Genital Diseases, Lower Urinary Tract Symptoms, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urological Manifestations, benign prostatic hyperplasia, male reproductive system disorder, prostate disorder | Active, not recruiting | Not applicable | 2026-09-14 | NCT04838769 | |
| DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Recruiting | Phase 2 | 2026-08-26 | NCT06059495 | |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-08-10 | NCT06731478 | |
| Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs) | cancer, neoplasm | Recruiting | Not applicable | 2026-07-10 | NCT05558644 | |
| UroCCR Database: French Research Network for Kidney Cancer -UroCCR | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, kidney cancer, kidney disorder, neoplasm, urinary system disorder | Recruiting | Not stated | 2026-06-25 | NCT03293563 | |
| SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2026-05-08 | NCT05826509 | |
| Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2026-03-16 | NCT05528952 | |
| Radiofrequency Ablation vs Doppler-guided Haemorrhoidal Artery Ligation in the Treatment of Haemorrhoidal Disease | Digestive System Diseases, cardiovascular disorder, digestive system disorder, hemorrhoid, intestinal disorder, rectal disorder, vascular disorder | Recruiting | Not applicable | 2026-03-13 | NCT06170736 | |
| Balloon-Expandable Versus Self-expanding Transcatheter Heart Valve for Treatment of Symptomatic Native Aortic Valve Stenosis (BEST) | Ventricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, cardiovascular disorder, heart disorder, heart valve disorder | Active, not recruiting | Not applicable | 2025-12-04 | NCT05454150 | |
| Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 3 | 2025-12-04 | NCT05201547 | |
| Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI | Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, carcinoma, carcinoma of the ampulla of vater, duodenal adenocarcinoma, endocrine system disorder, epithelial neoplasm, gastric adenocarcinoma, malignant endocrine neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, pancreatic adenocarcinoma, primitive neuroectodermal tumor, sarcoma, small intestine adenocarcinoma | Recruiting | Phase 2 | 2025-12-02 | NCT06333314 | |
| Multicentre Study of MITRACLIP® Transcatheter Mitral Valve Repair in Patients With Severe Primary Mitral Regurgitation Eligible for High-risk Surgery | cardiovascular disorder, heart disorder, heart valve disorder, mitral valve insufficiency | Active, not recruiting | Not applicable | 2025-11-26 | NCT03271762 | |
| First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 2 | 2025-09-22 | NCT06253611 | |
| Benefit on Chronic Pain of Early Screening and Management of Patients With Persistent Postoperative Pain at 3 Months | Chronic Postoperative Pain, Neurologic Manifestations, Pain, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Postoperative Pain, Signs and Symptoms | Not yet recruiting | Not applicable | 2025-09-08 | NCT07160595 | |
| Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. | Metastatic Pancreatic Adenocarcinoma | Active, not recruiting | Phase 2 | 2025-07-25 | NCT04348045 | |
| OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm, pancreatic ductal adenocarcinoma | Active, not recruiting | Phase 2 | 2025-07-25 | NCT03806309 | |
| ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Not stated | 2025-07-23 | NCT05787197 | |
| Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract cancer, biliary tract disorder, neoplasm | Recruiting | Not stated | 2025-07-23 | NCT04935853 | |
| Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. | Advanced Biliary Tract Carcinoma | Active, not recruiting | Phase 2 | 2025-07-23 | NCT03704480 | |
| QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 3 | 2025-07-18 | NCT03828227 | |
| Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. | Genomic Instability, Microsatellite Instability, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Active, not recruiting | Phase 2 | 2025-06-15 | NCT04006262 | |
| Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study. | Digestive System Diseases, Digestive System Neoplasms, Genomic Instability, Microsatellite Instability, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, malignant colon neoplasm, mismatch repair cancer syndrome 1, neoplasm | Not yet recruiting | Phase 2 | 2025-06-13 | NCT06646445 | |
| Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. | Colorectal Cancer Metastatic; MSI-H Colorectal Cancer | Active, not recruiting | Phase 2 | 2025-06-13 | NCT04730544 | |
| Management of Symptomatic Advanced Pancreatic Adenocarcinoma | Management Supportive Care Program; Pancreas | Active, not recruiting | Not applicable | 2025-06-13 | NCT02979483 |